Global Renal Denervation Devices Market, By Product Type (Percutaneous Renal Denervation, Radiofrequency Renal Denervation, Ultrasound Renal Denervation, and Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 903.9 Million in 2023 and is expected to exhibit a CAGR of 14.5% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Key market players are focusing on adopting growth strategies, such as launch of new products, which will drive the global renal denervation devices market growth. For instance, Medtronic, a medical device company, received the U.S. Food and Drug Administration approval for Symplicity Spyral renal denervation system for use in the U.S.
Global Renal Denervation Devices Market – Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019 as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems with regard to the transportation of things from one place to another.
COVID-19 had a negative impact on the global renal denervation devices market owing to manufacturing and supply chain of medical devices getting hampered due to lockdowns imposed globally.
Global Renal Denervation Devices Market: Key Developments
In November 10, 2023, Recor Medical, Inc., a medical device company, announced the first commercial use of Recor’s Paradise Ultrasound Renal Denervation (uRDN) system for the treatment of hypertension, the first US FDA approved renal denervation therapy in the U.S.
Browse 26 Market Data Tables and 28 Figures spread through 138 Pages and in-depth TOC on “Global Renal Denervation Devices Market”- Forecast to 2030, Global Renal Denervation Devices Market, By Product Type (Percutaneous Renal Denervation, Radiofrequency Renal Denervation, Ultrasound Renal Denervation, and Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
Link: https://www.coherentmarketinsights.com/market-insight/renal-denervation-devices-market-798
Key Takeaways of the Global Renal Denervation Devices Market:
- The global renal denervation devices market is expected to exhibit a CAGR of 14.5% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global renal denervation devices market.
- Among procedure type, the percutaneous renal denervation segment is expected to hold a dominant position in the global renal denervation devices market during the forecast period, and this is attributed innovative product launches by the market players
- Among region, North America is expected to be the dominant region in the global renal denervation devices market owing to the key players focusing on organic strategies to start new product launches
- Major players operating in the global renal denervation devices market are Medtronic, Recor Medical, Inc., Boston Scientific Corp, Kona Medical, Terumo Corporation, Abbott, Ablative Solutions, and others
